FI
PVLA

Fosun International’s Palvella Therapeutics PVLA Stock Holding History

Fosun International’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,559
Closed -$1.62M – 296
2019
Q2 		$1.62M Buy
4,559
+1,775
+64% +$529K 0.11% 125
2019
Q1 		$710K Buy
2,784
+438
+19% +$104K 0.05% 192
2018
Q4 		$479K Buy
+2,346
New +$728K 0.03% 226

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Fosun International's PVLA Position: Q3 2019 in Review

Fosun International sold out of Palvella Therapeutics (PVLA) in Q3 2019, closing a stake of 4,559 shares — an estimated $1.62M sold.

Fosun International first reported a position in PVLA in Q4 2018 and held it in 3 quarters. The position peaked at $1.62M in Q2 2019. 98 funds tracked by Wall St. Rank hold PVLA as of Q3 2019.

  • Fosun International reported no remaining Palvella Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 4,559 Palvella Therapeutics shares in Q3 2019, an estimated $1.62M.
  • Fosun International first reported a position in Palvella Therapeutics in Q4 2018 and held it in 3 quarters.
  • Fosun International's Palvella Therapeutics position peaked at $1.62M in Q2 2019.
  • 98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.